Piper Sandler Maintains Overweight on Cue Biopharma, Raises Price Target to $8
Benzinga · 11/06/2023 15:40
Piper Sandler analyst Edward Tenthoff maintains Cue Biopharma (NASDAQ:CUE) with a Overweight and raises the price target from $7 to $8.